Summary: Evaluated atorvastatin versus placebo given to diabetic patients for primary prevention of major adverse cardiac events (MACE). Major benefit was seen with atorvastatin including all-cause mortality reduction, acute coronary syndrome reduction, stroke reduction, and coronary revascularization reduction. About 2/3 of patients in this trial had LDL levels at goal prior to starting atorvastatin. All diabetics are now recommended to be on statin therapy regardless of their LDL level.
Lancet. 2004 Aug 21-27;364(9435):685-96.
Eponym: Collaborative AtoRvastatin Diabetes Study